Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present UroGen Pharma Ltd. (NASDAQ: URGN).

Full DD Report for URGN

You must become a subscriber to view this report.


Recent News from (NASDAQ: URGN)

UroGen Pharma (URGN) CEO Ron Bentsur on Q2 2018 Results - Earnings Call Transcript
UroGen Pharma (URGN) Q2 2018 Earnings Conference Call August 14, 2018, 08:30 AM ET Executives Catherine Bechtold - Director of Corporate Communications and IR Ron Bentsur - CEO Mark Schoenberg - Chief Medical Officer Stephen Mullennix - COO Analysts Boris Peaker - Cowen ...
Source: SeekingAlpha
Date: August, 14 2018 14:46
UroGen Pharma misses by $0.25
UroGen Pharma (NASDAQ: URGN ): Q2 EPS of -$1.14 misses by $0.25 . More news on: UroGen Pharma, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 14 2018 07:05
UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments
Plan to Initiate Q4 2018 Rolling New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for UGN-101, Ahead of Initial Projection of Q1 2019 Initiated Phase 2b Clinical Trial of UGN-102 (VesiGel™) f or the Treatment of Low-Grade Non-Muscle ...
Source: GlobeNewswire
Date: August, 14 2018 07:00
UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer
Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization RA’ANANA, Israel, and NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma...
Source: GlobeNewswire
Date: August, 08 2018 08:00
UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report second quarter 2018 financial results on Tuesday, August 14, 2018, prior to the open of...
Source: GlobeNewswire
Date: August, 07 2018 08:00
Playing The Expectations Game In Biotech
Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th...
Source: SeekingAlpha
Date: July, 17 2018 21:11
Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters
Stocks in News: TORC, RHHBY ResTORbio's RTB101 shows treatment benefit in mid-stage study; shares up 9% Discussion : ResTORbio ( TORC ) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infecti...
Source: SeekingAlpha
Date: July, 13 2018 04:16
UroGen Pharma submits Investigational New Drug application for UGN-102
UroGen Pharma (NASDAQ: URGN ) submitted to FDA an Investigational New Drug (NYSE: IND ) application for UGN-102 for the treatment of patients with low-grade non-muscle invasive bladder cancer at the end of Q2. More news on: UroGen Pharma, ING GROEP N V, Healthcare stocks news, Read m...
Source: SeekingAlpha
Date: July, 11 2018 09:02
UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel(TM)) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)
Company Expects to Begin U.S. Phase 2b Clinical Trial in Q3 2018 UGN-102 Has Potential to Become the First Front Line Non-Surgical Therapy for Patients with LG NMIBC RA’ANANA, Israel and NEW YORK, July 11, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical...
Source: GlobeNewswire
Date: July, 11 2018 08:00
UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors
Tomasello is a Renowned Industry Expert Responsible for the Commercialization of Revolutionary, Multi-Billion Dollar Products in Hematology-Oncology RA’ANANA, Israel and NEW YORK, July 10, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceuti...
Source: GlobeNewswire
Date: July, 10 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0844.5643.7545.1043.5964,372
2018-05-1763.9962.0463.9960.25158,282

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-115,5118,72863.1416Short
2018-12-1020,96423,73588.3253Short
2018-12-078,00912,87762.1962Short
2018-12-063,5667,66446.5292Short
2018-12-043,2817,04546.5720Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on URGN.


About UroGen Pharma Ltd. (NASDAQ: URGN)

Logo for UroGen Pharma Ltd. (NASDAQ: URGN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: URGN)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 15 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 25 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 16 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 15 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 20 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: February, 15 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: URGN)

      Daily Technical Chart for (NASDAQ: URGN)


      Stay tuned for daily updates and more on (NASDAQ: URGN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: URGN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in URGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of URGN and does not buy, sell, or trade any shares of URGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/